Literature DB >> 10394936

Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome.

L R Cornejo-Roldan1, E Roessler, M Muenke.   

Abstract

Pfeiffer syndrome (PS) is one of the classical craniosynostosis syndromes correlated with specific mutations in the human fibroblast growth factor receptor (FGFR) genes, FGFR1 and FGFR2. In this study, we set out to examine the exons in FGFR2 most commonly associated with mutations in PS, exons IIIa and IIIc, in a panel of 78 unrelated individuals with PS by the most sensitive method (direct DNA sequencing). We have identified a total of 18 different mutations among 40 patients; eight of these mutations have not been previously described. The mutational spectrum displays a non-random character with the frequent involvement of cysteine codons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394936     DOI: 10.1007/s004390050979

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

Review 1.  Pfeiffer type 2 syndrome: review with updates on its genetics and molecular biology.

Authors:  Rabjot Rai; Joe Iwanaga; Graham Dupont; Rod J Oskouian; Marios Loukas; W Jerry Oakes; R Shane Tubbs
Journal:  Childs Nerv Syst       Date:  2019-06-21       Impact factor: 1.475

2.  FGFR-associated craniosynostosis syndromes and gastrointestinal defects.

Authors:  Christine E Hibberd; Sarah Bowdin; Yamini Arudchelvan; Christopher R Forrest; Katherine A Brakora; Ralph S Marcucio; Siew-Ging Gong
Journal:  Am J Med Genet A       Date:  2016-08-02       Impact factor: 2.802

3.  A model for the pharmacological treatment of crouzon syndrome.

Authors:  Chad A Perlyn; Gillian Morriss-Kay; Tron Darvann; Marissa Tenenbaum; David M Ornitz
Journal:  Neurosurgery       Date:  2006-07       Impact factor: 4.654

Review 4.  FGF signaling in the developing endochondral skeleton.

Authors:  David M Ornitz
Journal:  Cytokine Growth Factor Rev       Date:  2005-04-01       Impact factor: 7.638

5.  Atypical Skin Manifestations in FGFR2-Related Craniosynostosis Syndromes Broaden the Phenotypic Spectrum.

Authors:  Shannon LeBlanc; David David; Alison Colley; Michael Buckley; Tony Roscioli; Christopher Barnett
Journal:  Mol Syndromol       Date:  2018-04-24

Review 6.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

7.  Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.

Authors:  Shih-hsin Kan; Navaratnam Elanko; David Johnson; Laura Cornejo-Roldan; Jackie Cook; Elsa W Reich; Susan Tomkins; Alain Verloes; Stephen R F Twigg; Sahan Rannan-Eliya; Donna M McDonald-McGinn; Elaine H Zackai; Steven A Wall; Maximilian Muenke; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2002-01-04       Impact factor: 11.025

8.  Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping.

Authors:  Pia Pinholt Madsen; Maria Kibaek; Xavier Roca; Ravi Sachidanandam; Adrian R Krainer; Ernst Christensen; Robert D Steiner; K Michael Gibson; Thomas J Corydon; Inga Knudsen; Ronald J A Wanders; Jos P N Ruiter; Niels Gregersen; Brage Storstein Andresen
Journal:  Hum Genet       Date:  2005-11-30       Impact factor: 4.132

Review 9.  Craniosynostosis: molecular pathways and future pharmacologic therapy.

Authors:  Kshemendra Senarath-Yapa; Michael T Chung; Adrian McArdle; Victor W Wong; Natalina Quarto; Michael T Longaker; Derrick C Wan
Journal:  Organogenesis       Date:  2012-10-01       Impact factor: 2.500

10.  Syndromic craniosynostosis.

Authors:  Christopher Derderian; James Seaward
Journal:  Semin Plast Surg       Date:  2012-05       Impact factor: 2.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.